Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Faculty of Medical Sciences, Utrecht University, Utrecht, The Netherlands.
ANZ J Surg. 2022 Jul;92(7-8):1772-1780. doi: 10.1111/ans.17699. Epub 2022 May 3.
Locally invasive T4 rectal cancer often requires neoadjuvant treatment followed by multi-visceral surgery to achieve a radical resection (R0), and referral to a specialized exenteration quaternary centre is typically recommended. The aim of this study was to explore regional variance in treatment and outcomes of patients with locally advanced rectal cancer in Australia and New Zealand (ANZ).
Data were collected from the Bi-National Colorectal Cancer Audit (BCCA) database. Rectal cancer patients treated between 2007 and 2019 were divided into six groups based on region (state/country) using patient postcode. A subset analysis of patients with T4 cancer was performed. Primary outcomes were positive circumferential resection margin (CRM+), and positive circumferential and/or distal resection margin (CRM/DRM+).
A total of 9385 patients with rectal cancer were identified, with an overall CRM+ rate of 6.4% and CRM/DRM+ rate of 8.6%. There were 1350 patients with T4 rectal cancer (14.4%). For these patients, CRM+ rate was 18.5%, and CRM/DRM+ rate was 24.1%. Significant regional variation in CRM+ (range 13.4-26.0%; p = 0.025) and CRM/DRM+ rates (range 16.1-29.3%; p = 0.005) was identified. In addition, regions with higher CRM+ and CRM/DRM+ rates reported lower rates of multi-visceral resections: range 24.3-26.8%, versus 32.6-37.3% for regions with lower CRM+ and CRM/DRM+ rates (p < 0.0001).
Positive resection margins and rates of multi-visceral resection vary between the different regions of ANZ. A small subset of patients with T4 rectal cancer are particularly at risk, further supporting the concept of referral to specialized exenteration centres for potentially curative multi-visceral resection.
局部侵袭性 T4 直肠肿瘤常需要新辅助治疗,然后进行多脏器手术以实现根治性切除(R0),通常建议转至专门的根治性切除术四级中心。本研究旨在探讨澳大利亚和新西兰(ANZ)局部晚期直肠肿瘤患者的治疗和结局的区域差异。
从双国家结直肠癌审计(BCCA)数据库中收集数据。根据患者邮政编码,将 2007 年至 2019 年期间治疗的直肠肿瘤患者分为六个组,按区域(州/国家)划分。对 T4 癌症患者进行了亚组分析。主要结局是阳性环周切缘(CRM+)和阳性环周及/或远端切缘(CRM/DRM+)。
共确定了 9385 例直肠肿瘤患者,总体 CRM+率为 6.4%,CRM/DRM+率为 8.6%。有 1350 例 T4 直肠肿瘤患者(14.4%)。这些患者的 CRM+率为 18.5%,CRM/DRM+率为 24.1%。CRM+(范围 13.4-26.0%;p=0.025)和 CRM/DRM+(范围 16.1-29.3%;p=0.005)率存在显著的区域差异。此外,CRM+和 CRM/DRM+率较高的区域报告的多脏器切除术比例较低:范围为 24.3-26.8%,而 CRM+和 CRM/DRM+率较低的区域为 32.6-37.3%(p<0.0001)。
ANZ 不同地区的切缘阳性率和多脏器切除术率存在差异。一小部分 T4 直肠肿瘤患者风险特别高,进一步支持转至专门的根治性切除术中心进行潜在治愈性多脏器切除术的概念。